PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 181 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic... May 14, 2026 Zantac Contains A Cancer-Causing Chemical And Now Breast Cancer Patients Are... September 30, 2019 Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... September 27, 2021 Median Survival Times for Two Forms of Advanced Breast Cancer Have... November 9, 2021 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel Women and girls in science: We won’t stop pushing for progress Efficacy and Safety of Adjuvant Pertuzumab, Trastuzumab and Chemotherapy After 6... FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer
